Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human ALK-1 Antibody, R&D Systems™
Mouse Monoclonal Antibody has been used in 3 publications
Supplier: R&D Systems MAB370500
This item is not returnable.
View return policy
Description
ALK-1 Monoclonal specifically detects ALK-1 in Human samples. It is validated for Western Blot, Simple Western.Specifications
ALK-1 | |
Monoclonal | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
activin A receptor type II-like 1, activin A receptor, type II-like kinase 1, Activin receptor-like kinase 1, ACVRL1, ACVRLK1ORW2, ALK1, ALK-1, ALK1TGF-B superfamily receptor type I, EC 2.7.11, HHT, HHT2EC 2.7.11.30, serine/threonine-protein kinase receptor R3, SKR3, TSR-I | |
Mouse | |
Protein A or G purified from ascites | |
RUO | |
94 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
IgG2a |
Western Blot | |
117720 | |
Western Blot 2 ug/mL, Simple Western 40 ug/mL | |
P37023 | |
ACVRL1 | |
Mouse myeloma cell line NS0-derived recombinant human ALK-1 Asp22-Gln118 Accession # P37023 | |
500 μg | |
Primary | |
Detects human ALK-1 in direct ELISAs and Western blots. Shows less than 1% cross-reactivity with recombinant mouse ALK-1, recombinant human (rh) Activin RIA, or rhActivin RIB. | |
Human | |
Ascites |
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?
Provide Content Correction